Apixaban Market: Research Analysis & Forecast 2026 By Top Vendors Bristol-Myers Squibb, Portola Pharmaceuticals, C. H. Boehringer Sohn, Pfizer, Roche, CoaguSense, Siemens, Alere, and Abbott

Apixaban is a Food and Drug Administrator (FDA) approved anticoagulant used for the treatment of venous thromboembolic events (blood clot) that forms within a vein. Venous thromboembolic events (VTE) can occur without any prior symptoms or warning signs and can go undiagnosed and unrecognized by a healthcare professional. Symptoms that do appear may be associated with pulmonary embolism (PE) or either deep vein thrombosis (DVT) such as pain in the calf, swelling in the ankle or foot, redness or noticeable discoloration spots, rapid breathing, chest pain, and others. Apixaban is sold under the trade-name of Eliquis. Factor Xa is a trypsin-like serine protease that plays a key role in blood coagulation cascade. Apixaban mechanism works on inhibiting factor Xa, which indirectly decreases the clot formation stimulated by thrombin. Apixaban is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. The recommended dose of Eliquis is 5mg orally twice a day. Apixaban is available in the market as capsules and tablet form.

Download PDF Brochure Of Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1898

Apixaban Market – Dynamics

Increasing prevalence of venous thromboembolism related conditions is expected to aid in growth of the apixaban market. For instance, according to International Society on Thrombosis and Haemostasis 2014 facts, revealed that around 10 million cases of venous thromboembolism occur annually across low, middle and high income countries. Moreover, increasing therapeutic indications for apixaban is expected to boost the apixaban market growth. For instance, in 2014, the U.S. Food and Drug Administration approved Eliquis for the treatment of deep vein thrombosis (DVT) prophylaxis and pulmonary embolism (PE) and also for the reduction in risk of recurrent PE and DVT following initial therapy. Furthermore, government and private organizations are significantly investing capital in healthcare research and development and this is also likely to propel growth of the Apixaban market. However, adverse effects of apixaban such as increased risk of thrombotic events after premature discontinuation and bleeding is expected to hamper adoption of this. This in turn is expected to adversely affect growth of the market. According to a study published in the Current Medical Research and Opinion 2017 stated about the bleeding risk associated with use of apixaban.

Apixaban Market – Taxonomy

On the basis of dosage form, the global apixaban market is segmented into:

Capsule
Tablet

On the basis of geography, the global apixaban market is segmented into:

North America
Latin America
Europe
Asia Pacific
Middle East
Africa

Request For Customization Of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/1898

Apixaban Market – Competitive Landscape

Major players operating in the global apixaban market include Bristol-Myers Squibb, Portola Pharmaceuticals, C. H. Boehringer Sohn, Pfizer, Roche, CoaguSense, Siemens, Alere, and Abbott. Market players are focusing on developing new technologies, and on mergers, and collaborations in order to gain dominant position in the market. For instance, in 2016, Pfizer and Bristol-Myers Squibb entered into collaboration with Portola Pharmaceuticals to commercialize and develop investigational Andexanet Alfa, a clinical phase 3 drug, which is developed to reverse the anticoagulant effect of Factor Xa inhibitors that will be helpful for patients experience a major bleeding issue on the use of Eliquis.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.